Discrepancies between clinical studies and the real-world results are expected and have been reported as up to 27%.16,17 Clinical studies on insulin therapy usually exclude subjects prone to hypoglycemia or diabetic ketoacidosis (DKA), thus potentially biasing the estimation of adverse events in these trials. The gene discussed is INS; the disease is Hypoglycemia.